<DOC>
	<DOCNO>NCT00334776</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell mixed tumor protein may help body build effective immune response kill melanoma cell . PURPOSE : This phase II trial study well vaccine therapy work treat patient metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical response HLA-A *0201-positive patient metastatic melanoma treat intradermally administer vaccine comprise autologous dendritic cell pulse MART-1 , gp100 , tyrosinase peptide mature cytokine cocktail . Secondary - Determine immunologic response patient treat regimen . OUTLINE : This multicenter study . Patients undergo apheresis collect dendritic cell ( DC ) . Autologous DC pulse ex vivo tumor antigen peptide derive MART-1 : 26-35 ( 27L ) , gp100 : 209-217 ( 210M ) , tyrosinase : 368-376 ( 370D ) mature cytokine cocktail comprise interleukin ( IL ) -4 , IL-6 , IL-1β , sargramostim ( GM-CSF ) , tumor necrosis factor-α , prostaglandin E2 . Patients receive 12 intradermal injection DC vaccine 30 minute day 1 , 8 , 22 , 36 . Treatment repeat every 8 week 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically disease progression . PROJECTED ACCRUAL : A total 41 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis melanoma Metastatic disease The following melanoma subtypes eligible : Unresectable , stage IIIIV uveal melanoma Metastatic mucosal melanoma Measurable disease attempt curative surgical therapy Tumor tissue must available immunohistochemical stain Positive ≥ 1 follow peptide : MART1 : 2635 ( 27L ) gp100 : 209217 ( 210M ) Tyrosinase : 368376 ( 370D ) HLAA *0201 positive DNA polymerase chain reaction assay PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky PS 70100 % Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 2.0 mg/dL WBC ≥ 3,000/mm^3 Platelet count ≥ 75,000/mm^3 Hemoglobin ≥ 9.0 g/dL No major systemic infection No coagulation disorder No major medical illness cardiovascular respiratory system No myocardial infarction within past 6 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity No know positivity hepatitis B surface antigen hepatitis C antibody No prior uveitis autoimmune inflammatory eye disease No prior malignancy except cervical carcinoma situ basal cell skin cancer unless patient curatively treat &gt; 5 year ago detectable disease PRIOR CONCURRENT THERAPY : See Disease Characteristics No 1 prior cytotoxic chemotherapy agent regimen Prior biologic antiangiogenic therapy allow More 1 month since prior concurrent radiotherapy , chemotherapy , adjuvant therapy , therapy melanoma No prior MART1 : 2635 ( 27L ) , gp100 : 209217 ( 210M ) , tyrosinase : 368376 ( 370D ) peptides No concurrent steroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>extraocular extension melanoma</keyword>
</DOC>